Validation study demonstrates florbetapir-PET correlation with brain beta-amyloid density during life, suggesting potential utility in diagnosing Alzheimer disease.
Florbetapir-PET imaging was correlated with the presence and density of β-amyloid. These data provide evidence that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life. Additional studies are required to understand the appropriate use of florbetapir-PET imaging in the clinical diagnosis of Alzheimer disease and for the prediction of progression to dementia.
No takes yet. Share an insight, caveat, or question.
Christopher M. Clark (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: